Studying the effects of vitamin E and selenium for Alzheimer's disease prevention: The preadvise model

Allison M. Caban-Holt; Frederick A. Schmitt; C. R. Runyons; R. J. Kryscio; M. S. Mendiondo; M. S. Healey; W. R. Markesbery; C. A. Coltman; J. J. Crowley; P. J. Goodman; J. L. Hartline

Studying the effects of vitamin E and selenium for Alzheimer's disease prevention: The preadvise model

Allison M. Caban-Holt
, Frederick A. Schmitt
, C. R. Runyons
, R. J. Kryscio
, M. S. Mendiondo
, M. S. Healey
, W. R. Markesbery
, C. A. Coltman
, J. J. Crowley
, P. J. Goodman
, J. L. Hartline

Producción científica: Chapter › revisión exhaustiva

5 Citas (Scopus)

Resumen

Alzheimer's disease (AD) currently affects over 4 million Americans, and these numbers are expected to increase three-fold over the next 50 years. Worldwide prevalence is estimated to be between 18 and 34 million individuals. Though the etiologies of AD continue to remain elusive, the prevention of AD is becoming a critical focus for treatment. The PREADVISE study is investigating the long-term use of antioxidant supplements vitamin E and selenium for the prevention of AD. Further, PREADVISE is utilizing an innovative sub-study model in cooperation with the SELECT prostate cancer trial and has thus far accrued over 5,100 participants. This article introduces the PREADVISE/SELECT ancillary study model and discusses its potential benefits for conducting large-scale, longitudinal, clinical trials in dementia research.

Idioma original	English
Título de la publicación alojada	Research and Practice in Alzheimer's Disease
Editores	B. Vellas, E. Giacobini
Páginas	124-130
Número de páginas	7
Estado	Published - 2006

Serie de la publicación

Nombre	Research and Practice in Alzheimer's Disease
Volumen	11
ISSN (versión impresa)	1284-8360

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Good health and well being

ASJC Scopus subject areas

Neuropsychology and Physiological Psychology
Aging
Geriatrics and Gerontology
Biological Psychiatry

Otros archivos y enlaces

Citar esto

Caban-Holt, A. M., Schmitt, F. A., Runyons, C. R., Kryscio, R. J., Mendiondo, M. S., Healey, M. S., Markesbery, W. R., Coltman, C. A., Crowley, J. J., Goodman, P. J., & Hartline, J. L. (2006). Studying the effects of vitamin E and selenium for Alzheimer's disease prevention: The preadvise model. En B. Vellas, & E. Giacobini (Eds.), Research and Practice in Alzheimer's Disease (pp. 124-130). (Research and Practice in Alzheimer's Disease; Vol. 11).

@inbook{73530e8b0cb245ae8134cf15ddc14d51,

title = "Studying the effects of vitamin E and selenium for Alzheimer's disease prevention: The preadvise model",

abstract = "Alzheimer's disease (AD) currently affects over 4 million Americans, and these numbers are expected to increase three-fold over the next 50 years. Worldwide prevalence is estimated to be between 18 and 34 million individuals. Though the etiologies of AD continue to remain elusive, the prevention of AD is becoming a critical focus for treatment. The PREADVISE study is investigating the long-term use of antioxidant supplements vitamin E and selenium for the prevention of AD. Further, PREADVISE is utilizing an innovative sub-study model in cooperation with the SELECT prostate cancer trial and has thus far accrued over 5,100 participants. This article introduces the PREADVISE/SELECT ancillary study model and discusses its potential benefits for conducting large-scale, longitudinal, clinical trials in dementia research.",

keywords = "Alzheimer's disease, Antioxidants, Cognitive screening, PREADVISE, Prevention, SELECT, Study models",

author = "Caban-Holt, \{Allison M.\} and Schmitt, \{Frederick A.\} and Runyons, \{C. R.\} and Kryscio, \{R. J.\} and Mendiondo, \{M. S.\} and Healey, \{M. S.\} and Markesbery, \{W. R.\} and Coltman, \{C. A.\} and Crowley, \{J. J.\} and Goodman, \{P. J.\} and Hartline, \{J. L.\}",

year = "2006",

language = "English",

isbn = "2914377959",

series = "Research and Practice in Alzheimer's Disease",

pages = "124--130",

editor = "B. Vellas and E. Giacobini",

booktitle = "Research and Practice in Alzheimer's Disease",

}

Caban-Holt, AM, Schmitt, FA, Runyons, CR, Kryscio, RJ, Mendiondo, MS, Healey, MS, Markesbery, WR, Coltman, CA, Crowley, JJ, Goodman, PJ & Hartline, JL 2006, Studying the effects of vitamin E and selenium for Alzheimer's disease prevention: The preadvise model. En B Vellas & E Giacobini (eds.), Research and Practice in Alzheimer's Disease. Research and Practice in Alzheimer's Disease, vol. 11, pp. 124-130.

Studying the effects of vitamin E and selenium for Alzheimer's disease prevention: The preadvise model. / Caban-Holt, Allison M.; Schmitt, Frederick A.; Runyons, C. R. et al.
Research and Practice in Alzheimer's Disease. ed. / B. Vellas; E. Giacobini. 2006. p. 124-130 (Research and Practice in Alzheimer's Disease; Vol. 11).

Producción científica: Chapter › revisión exhaustiva

TY - CHAP

T1 - Studying the effects of vitamin E and selenium for Alzheimer's disease prevention

T2 - The preadvise model

AU - Caban-Holt, Allison M.

AU - Schmitt, Frederick A.

AU - Runyons, C. R.

AU - Kryscio, R. J.

AU - Mendiondo, M. S.

AU - Healey, M. S.

AU - Markesbery, W. R.

AU - Coltman, C. A.

AU - Crowley, J. J.

AU - Goodman, P. J.

AU - Hartline, J. L.

PY - 2006

Y1 - 2006

N2 - Alzheimer's disease (AD) currently affects over 4 million Americans, and these numbers are expected to increase three-fold over the next 50 years. Worldwide prevalence is estimated to be between 18 and 34 million individuals. Though the etiologies of AD continue to remain elusive, the prevention of AD is becoming a critical focus for treatment. The PREADVISE study is investigating the long-term use of antioxidant supplements vitamin E and selenium for the prevention of AD. Further, PREADVISE is utilizing an innovative sub-study model in cooperation with the SELECT prostate cancer trial and has thus far accrued over 5,100 participants. This article introduces the PREADVISE/SELECT ancillary study model and discusses its potential benefits for conducting large-scale, longitudinal, clinical trials in dementia research.

AB - Alzheimer's disease (AD) currently affects over 4 million Americans, and these numbers are expected to increase three-fold over the next 50 years. Worldwide prevalence is estimated to be between 18 and 34 million individuals. Though the etiologies of AD continue to remain elusive, the prevention of AD is becoming a critical focus for treatment. The PREADVISE study is investigating the long-term use of antioxidant supplements vitamin E and selenium for the prevention of AD. Further, PREADVISE is utilizing an innovative sub-study model in cooperation with the SELECT prostate cancer trial and has thus far accrued over 5,100 participants. This article introduces the PREADVISE/SELECT ancillary study model and discusses its potential benefits for conducting large-scale, longitudinal, clinical trials in dementia research.

KW - Alzheimer's disease

KW - Antioxidants

KW - Cognitive screening

KW - PREADVISE

KW - Prevention

KW - SELECT

KW - Study models

UR - https://www.scopus.com/pages/publications/33847040744

UR - https://www.scopus.com/pages/publications/33847040744#tab=citedBy

M3 - Chapter

AN - SCOPUS:33847040744

SN - 2914377959

SN - 9782914377959

T3 - Research and Practice in Alzheimer's Disease

SP - 124

EP - 130

BT - Research and Practice in Alzheimer's Disease

A2 - Vellas, B.

A2 - Giacobini, E.

ER -

Studying the effects of vitamin E and selenium for Alzheimer's disease prevention: The preadvise model

Resumen

Serie de la publicación

ODS de las Naciones Unidas

ASJC Scopus subject areas

Otros archivos y enlaces

Huella

Citar esto